Applied DNA Sciences director acquires 18,691 shares, holds 18,694
Applied DNA Sciences reported an insider equity change on a Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Applied DNA Sciences reported an insider equity change on a Form 4. A director acquired 18,691 shares of common stock on 10/17/2025 with a reported price of $0 (transaction code A). Following the transaction, the reporting person beneficially owns 18,694 shares, held directly.
The filing notes that 100% of the restricted stock units vest upon 90 days from the date of grant, indicating the award structure tied to service over a short vesting period.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 18,691 | $0.00 | $0.00 |
Footnotes (1)
- F1. 100% of the restricted stock units vest upon 90 days from the date of grant
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did APDN report in this Form 4?
What is the transaction code and what does it signify?
What vesting terms are disclosed for the award?
What is the reporting person’s relationship to APDN?
Was the ownership reported as direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.